Literature DB >> 19924140

Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls.

Kristina M Michael1, Tim Waterboer, Herbert Pfister, Marisa Gariglio, Slawomir Majewski, Michel Favre, Michael Pawlita.   

Abstract

Epidermodysplasia verruciformis (EV) is a rare recessive genodermatosis characterized by high susceptibility to infections with human papillomaviruses (HPVs) of genus beta. Knowledge about seroreactivity against HPV in these patients and their first-degree relatives is scarce. Using multiplex serology, we analyzed antibodies to 38 HPV types from five genera in 32 EV patients, 22 first-degree relatives, and 64 and 44 age- and sex-matched, non-related, healthy controls, respectively. EV patients showed higher seroprevalences than non-related controls with statistically significant odds ratios (ORs) for 5 of 10 investigated alpha (OR range 6.9-21.3), all 16 beta (OR range 12.3-61.3), 3 of 9 gamma (OR range 6.4-11.7), and 1 of 2 micro HPVs (OR 5.8). In comparison to their relatives, antibodies in EV patients were significantly more prevalent for 4 of 16 beta HPVs (OR range 12.5-25.6), but for none of the other genera. A significantly increased seroprevalence in relatives compared with their controls was only seen for HPV 5 (OR 22.1). The considerably elevated HPV seroprevalence in EV patients, especially for beta papillomaviruses (PVs), reflects the high viral load described for these individuals. Whether the observed differences between relatives and healthy controls depend on heterozygosity for EV-associated alleles requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924140     DOI: 10.1038/jid.2009.356

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  [Biology of epidermodysplasia verruciformis-associated HPV].

Authors:  H Pfister
Journal:  Hautarzt       Date:  2011-01       Impact factor: 0.751

Review 2.  Human papillomaviruses: shared and distinct pathways for pathogenesis.

Authors:  Denise A Galloway; Laimonis A Laimins
Journal:  Curr Opin Virol       Date:  2015-09-20       Impact factor: 7.090

3.  Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Sofie H Mooij; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

Review 4.  [Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream].

Authors:  A Heratizadeh; B Völker; E Kupsch; K Wichmann; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

Review 5.  Human genetic and immunological dissection of papillomavirus-driven diseases: new insights into their pathogenesis.

Authors:  Vivien Béziat; Jean-Laurent Casanova; Emmanuelle Jouanguy
Journal:  Curr Opin Virol       Date:  2021-09-21       Impact factor: 7.090

Review 6.  Epidemiology and biology of cutaneous human papillomavirus.

Authors:  Emily M Nunes; Valéria Talpe-Nunes; Laura Sichero
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

7.  Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses.

Authors:  Sarah J de Jong; Elias Imahorn; Peter Itin; Jouni Uitto; Gérard Orth; Emmanuelle Jouanguy; Jean-Laurent Casanova; Bettina Burger
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.